Compare SOBR & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | GRI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 18 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | 2008 | 2020 |
| Metric | SOBR | GRI |
|---|---|---|
| Price | $1.00 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 273.1K | ★ 380.3K |
| Earning Date | 04-10-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,421.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.35 | $0.18 |
| 52 Week High | $3.95 | $6.70 |
| Indicator | SOBR | GRI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Sobr Safe Inc is a hardware and software company. The Company integrates proprietary software, SOBRsafeTM, with its patented touch-based personal alcohol awareness tracking products, SOBRcheckTM and SOBRsure, enabling non-invasive personal alcohol awareness tracking, biometric identity verification, and qualified, real-time cloud-based, informational alerts and reporting. It operates as a single segment designed to enable customers to purchase products directly through channel partners, sales agents or through its enterprise and consumer digital channels. Currently its principal markets are located in North America.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.